GenEditBio Limited

Based in Hong Kong, China, and founded in 2021, GenEditBio Limited operates as a biotechnology company that focuses on the underlying technology of gene editing tools development. It has sub-branch offices in Beijing and Boston. The co-founder and chairman of the company, Zongli Zheng graduated from Harvard Medical School. The co-founder and CEO of the company, Tian Zhu graduated from the University of Illinois at Chicago and has worked in Jacobio and Betta.

In September 2024, GenEditBio closed a strategic investment from new investor Gobi Partners. The company mainly provides potentially curative gene editing-based solutions for genetic diseases. It has developed CRISPR-based (Clustered Regularly Interspaced Short Palindromic Repeats) gene editing tools and an off-target assessment technology platform. The company has three solutions to tackle bottlenecks restricting in vivo gene editing therapy, which are novel Cas (CRISPR-associated protein) nucleases mining and optimization, lead editor, and development of next-generation delivery tools.

GenEditBio has 5 product pipelines under study. The company also provides gene-editing drugs based on platforms and tools. The company generates revenue by providing gene editing-based solutions. The company will use the funding to support the development of the organization's vivo programs to enhance its capabilities in genome editing.